Last reviewed · How we verify
Methylphenidate Hydrochloride Controlled-Release Capsules
Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity in the brain by blocking their reuptake at the presynaptic neuron.
Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity in the brain by blocking their reuptake at the presynaptic neuron. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.
At a glance
| Generic name | Methylphenidate Hydrochloride Controlled-Release Capsules |
|---|---|
| Also known as | Foquest |
| Sponsor | McMaster University |
| Drug class | Central nervous system stimulant |
| Target | Dopamine transporter (DAT) and norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Neurology/Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Methylphenidate inhibits the reuptake of dopamine and norepinephrine, leading to increased concentrations of these neurotransmitters in the synaptic cleft. This enhanced neurotransmitter activity improves attention, focus, and impulse control. The controlled-release formulation provides sustained drug delivery over an extended period, allowing for once-daily dosing.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD)
- Narcolepsy
Common side effects
- Insomnia
- Decreased appetite
- Headache
- Nervousness or anxiety
- Tachycardia
- Abdominal pain
Key clinical trials
- A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity (PHASE4)
- Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) (PHASE4)
- A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants. (PHASE4)
- A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD (PHASE4)
- Real World Evidence of the Efficacy and Safety of FOQUEST (PHASE4)
- Effect of Pycnogenol® on ADHD (PHASE3)
- Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits (PHASE2)
- Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: